GlassScriptPhysician profile
Kate Newman
NPI 1942434881
$78,340.67
in general payments reported to CMS, 2019-2025
36 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,285 · 2022: $4,845 · 2023: $1,674 · 2024: $19K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Travel and Lodging: $13K · Food and Beverage: $7,473 · Consulting Fee: $4,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,726.86 |
| Travel and Lodging | $12,547.35 |
| Food and Beverage | $7,473.32 |
| Consulting Fee | $4,462.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $64,524.61 | 2021-2025 | Tremfya, Stelara, Remicade |
| Phathom Pharmaceuticals, INC. | $3,811.52 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $2,288.88 | 2021-2022 | |
| Abbvie INC. | $2,254.31 | 2021-2025 | |
| Celgene Corporation | $1,359.10 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $592.28 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $547.25 | 2022-2025 | |
| Pfizer INC. | $494.57 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.76 | 2021-2025 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $261.90 | 2021-2024 | Ocaliva |
| Qol Medical, LLC | $180.50 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $172.33 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $153.42 | 2021-2024 | Dificid |
| Organon LLC | $145.92 | 2021-2024 | Renflexis, Hadlima |
| Evoke Pharma, INC. | $135.00 | 2023-2025 | Gimoti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $121.60 | 2021 | |
| Amgen INC. | $88.39 | 2021-2023 | Amjevita, Avsola |
| Ironwood Pharmaceuticals, INC | $75.61 | 2022-2025 | Linzess |
| Ipsen Biopharmaceuticals, INC | $70.49 | 2024-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $65.18 | 2021-2022 | |
| Daiichi Sankyo INC. | $60.93 | 2022-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.50 | 2023-2024 | Cyltezo |
| Braintree Laboratories, INC. | $53.95 | 2021-2024 | Sutab, Suflave |
| Novo Nordisk INC | $51.74 | 2025 | |
| Lilly USA, LLC | $48.30 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $45.43 | 2024 | Resmetirom |
| Gilead Sciences, INC. | $42.80 | 2022-2024 | |
| Redhill Biopharma INC. | $41.68 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $40.85 | 2021-2024 | Rebyota |
| Ardelyx, INC. | $40.12 | 2024-2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $35.72 | 2023-2024 | Idacio |
| Albireo Pharma, INC. | $28.26 | 2024 | Bylvay |
| Aimmune Therapeutics, INC. | $28.15 | 2024-2025 | Vowst |
| Celltrion USA INC. | $19.66 | 2024 | Vegzelma |
| Alexion Pharmaceuticals, INC. | $18.71 | 2022 | |
| Mirum Pharmaceuticals, INC. | $17.25 | 2023 | Livmarli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.